Login or sign up
For business

CellProtect Nordic Pharmaceuticals AB

4.0ยท 12 reviews
Average ratingGreat
4.0/ 5

Based on 12 reviews

533%
433%
333%
20%
10%
Ask AI

Ask AI about CellProtect Nordic Pharmaceuticals AB

Generated with AI from 12 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website โ€” a simple way to convert your visitors into customers.

Get the widget for your site →

About CellProtect Nordic Pharmaceuticals AB

CellProtect Nordic Pharmaceuticals AB has developed an IP-protected process for GMP manufacturing of the NK-cell based drug candidate CellProtect for treatment of multiple myeloma. There are solid preclinical data showing that NK-cells expanded with the patented technology have restored cytotoxic activity and ability to selectively kill myeloma tumour cells. A Phase I / II clinical trial in multiple myeloma patients has been performed where CellProtect has been studied as an adjunct therapy to autologous stem cell transplantation. The results are very promising and CellProtect in the clinical trials shows a good safety profile. CellProtect was recently granted orphan drug designation from the European Commission for the treatment of multiple myeloma.